Pulmatrix (PULM) Change in Receivables (2018 - 2025)
Pulmatrix (PULM) posted Change in Receivables of $16000.0 for Q1 2025, up 169.57% sequentially from -$23000.0 in Q4 2024, and up 104.47% YoY from $7825.1 in Q1 2024.
Pulmatrix (PULM) Change in Receivables (2018 - 2025) Analysis & Trends
Pulmatrix has reported Change in Receivables for 7 years, with the latest figure at $16000.0 in Q1 2025.
- Quarterly Change in Receivables rose 104.47% year-over-year to $16000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$554000.0 (down 225.88% YoY) and the FY2024 annual result came in at -$928000.0, down 150.81% from the prior year.
- Change in Receivables improved to $16000.0 in Q1 2025 per PULM's latest filing, from -$23000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $1.7 million in Q2 2021 and troughed at -$1.8 million in Q3 2021.
- A 5-year average of -$4000.0 and a median of $3000.0 in 2021 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2022: Change in Receivables sank 303.36% in 2021, then soared 34766.67% in 2022.
- Over 5 years, Change in Receivables stood at $58000.0 in 2021, then soared by 1317.24% to $822000.0 in 2022, then sank by 89.42% to $87000.0 in 2023, then slumped by 126.44% to -$23000.0 in 2024, then jumped by 169.57% to $16000.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered $16000.0, -$23000.0, and -$612000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | -23,000.00 |
| Dec 31, 2024 | -23,000.00 |
| Sep 30, 2024 | -612,000.00 |
| Sep 30, 2024 | -612,000.00 |
| Jun 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 65,000.00 |
| Mar 31, 2024 | -358,000.00 |
| Mar 31, 2024 | -358,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Dec 31, 2023 | 87,000.00 |
| Sep 30, 2023 | 423,000.00 |
| Sep 30, 2023 | 423,000.00 |
| Jun 30, 2023 | -322,000.00 |
| Jun 30, 2023 | -322,000.00 |
| Mar 31, 2023 | -558,000.00 |
| Mar 31, 2023 | -558,000.00 |
| Dec 31, 2022 | 822,000.00 |
| Dec 31, 2022 | 822,000.00 |